Medical News Today: Osteoporosis drugs may lower mortality risk by 34%
Two recent studies reveal that people who take the correct medication for osteoporosis appear to have a significantly lower risk of premature death.
In this study, a metabolomics approach was applied to screen and identify biomarkers potentially associated with the anti-osteoporotic effect of a novel sialoglycoprotein isolated from the eggs of Carassius auratus (Ca-SGP). The alterations in serum metabolome following the stimulation by either an OVX-induced osteoporosis or the Ca-SGP treatment were investigated using a UPLC/Q-TOF MS platform. Results showed significant differences in the metabolic profiles between the control and the model group, as well as between the model and the Ca-SGP treated group, as revealed by PLS-DA. Further, several metabolites such as xanthi...
BUDAPEST, Hungary, Aug. 20, 2019 -- (Healthcare Sales &Marketing Network) -- Gedeon Richter Plc. ("Richter") today announced that it has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the sam... Biopharmaceuticals, Product Launch Gedeon Richter, biosimilar, teriparatide, Terrosa, Forsteo, osteoporosis
Conclusion: High glucose suppresses osteogenic differentiation in MC3T3 and sema3a may take part in this process. The application of exogenous sema3a alleviates high glucose-induced inhibition of osteoblast differentiation in diabetic osteopathy.
PMID: 31426065 [PubMed - in process]
This meta-analysis examines randomized placebo-controlled clinical trials of drug treatments, particularly treatment with bisphosphonates, for the prevention of fracture in patients with osteoporosis to assess whether these treatments are associated with reduced overall mortality rates.
We report a case of bilateral AFFs. The surgical treatments were the same, but the final treatment outcomes were different with or without teriparatide treatment. We investigated the potential causes of the different outcomes of AFFs between the two sides to inform the clinical treatment of AFFs.
AbstractPurpose of ReviewBone and muscle mass increase in response to mechanical loading and biochemical cues. Bone-forming osteoblasts differentiate into early osteocytes which ultimately mature into late osteocytes encapsulated in stiff calcified matrix. Increased muscle mass originates from muscle stem cells (MuSCs) enclosed between their plasma membrane and basal lamina. Stem cell fate and function are strongly determined by physical and chemical properties of their microenvironment, i.e., the cell niche.Recent FindingsThe cellular niche is a three-dimensional structure consisting of extracellular matrix components, si...
Authors: Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE Abstract Objective: To evaluate, post hoc, the efficacy and safety of abaloparatide by degree of renal impairment. Methods: ACTIVE was a phase 3, 18-month, randomized, double-blind, active-comparator, placebo-controlled study of postmenopausal women with osteoporosis who received subcutaneous abaloparatide 80 µg, placebo, or open-label teriparatide 20 µg daily. Patients with serum creatinine>2.0 mg/dL or 1.5-2.0 mg/dL with an estimated glomerular filtration rate (eGFR)
Publication date: Available online 16 August 2019Source: Clinica Chimica ActaAuthor(s): Yoshiki Nishizawa, Masakazu Miura, Shoichi Ichimura, Masaaki Inaba, Yasuo Imanishi, Masataka Shiraki, Junichi Takada, Osamu Chaki, Hiroshi Hagino, Masao Fukunaga, Saeko Fujiwara, Takami Miki, Noriko Yoshimura, Hiroaki Ohta, from the Japan Osteoporosis Society Bone Turnover Marker Investigation CommitteeAbstractWith the aging of society, the number of osteoporosis-related fractures is increasing. Prevention of osteoporosis and maintenance of the quality of life of osteoporosis patients require early diagnosis, effective treatment, and hi...
Conclusions. The meta-analysis showed that patients treated with vertebroplasty were associated with better pain relief and improved quality of life, without increasing the incidence of vertebral fracture compared with the CT group. PMID: 31423902 [PubMed - as supplied by publisher]